XML 39 R28.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaborative Arrangements (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2018
Collaborative Arrangements [Abstract] |
Collaboration Arrangements | Summarized information related to this collaboration is as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
($ in millions) | 2018 |  | 2017 |  | 2018 |  | 2017
Alliance revenues | $ | 49 |  |  | $ | 5 |  |  | $ | 125 |  |  | $ | 5 |
Materials and production (1) | 12 |  |  | — |  |  | 48 |  |  | — |
Marketing and administrative | 12 |  |  | — |  |  | 28 |  |  | — |
Research and development (2) | 47 |  |  | 2,377 |  |  | 118 |  |  | 2,377 |
($ in millions) |  |  |  |  | September 30, 2018 |  | December 31, 2017
Receivables from AstraZeneca |  |  |  |  | $ | 46 |  |  | $ | 12 |
Payables to AstraZeneca (3) |  |  |  |  | 892 |  |  | 643 |
(1) Represents amortization of capitalized milestone payments. (2) Amounts for the third quarter and first nine months of 2017 include $2.35 billion related to the upfront payment and future license option payments. (3) Includes accrued milestone and license option payments. Summarized information related to this collaboration is as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
($ in millions) | 2018 |  | 2017 |  | 2018 |  | 2017
Net product sales recorded by Merck | $ | 47 |  |  | $ | 38 |  |  | $ | 138 |  |  | $ | 105 |
Merck’s profit share from sales in Bayer’s marketing territories | 47 |  |  | 32 |  |  | 100 |  |  | 116 |
Total sales | 94 |  |  | 70 |  |  | 238 |  |  | 221 |
Materials and production (1) | 29 |  |  | 25 |  |  | 188 |  |  | 73 |
Marketing and administrative | 11 |  |  | 6 |  |  | 26 |  |  | 18 |
Research and development | 34 |  |  | 27 |  |  | 90 |  |  | 78 |
($ in millions) |  |  |  |  | September 30, 2018 |  | December 31, 2017
Receivables from Bayer |  |  |  |  |  | $ | 36 |  |  | $ | 33 |
Payables to Bayer (2) |  |  |  |  |  | 375 |  |  | 352 |
(1) Includes amortization of intangible assets. (2) Includes accrued milestone payments. Summarized information related to this collaboration is as follows:
($ in millions) | Three Months Ended September 30, 2018 |  | Nine Months Ended September 30, 2018
Alliance revenues | $ | 43 |  |  | $ | 78 |
Materials and production (1) | 8 |  |  | 9 |
Marketing and administrative | 5 |  |  | 7 |
Research and development (2) | 36 |  |  | 1,473 |
($ in millions) |  |  | September 30, 2018
Receivables from Eisai |  |  | $ | 42 |
Payables to Eisai (3) |  |  | 733 |
(1) Represents amortization of capitalized milestone payments. (2) Amount for the first nine months of 2018 includes $1.4 billion related to the upfront payment and future license option payments. (3) Includes accrued milestone and license option payments.

X
- Definition Collaborative Arrangements [Abstract] + References No definition available. + Details
Name: | mrk_CollaborativeArrangementsAbstract
Namespace Prefix: | mrk_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration